Twilight Litaka Pharma
Twilight Litaka Pharma
HealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -38.9% over past five years.
- Company has high debtors of 2,342 days.
- Working capital days have increased from 467 days to 1,003 days
Growth Rate
Quarterly Results
| Particulars | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 20.29 | 11.05 | 10.01 | 9.26 | 9.06 | 3.17 | 2.3 | 4.35 | 2.77 |
| Expenses | 49.12 | 51.26 | 23.41 | 10.32 | 9.47 | 2.43 | 1.85 | 2.09 | 4.31 |
| Operating Profit | -28.83 | -40.21 | -13.4 | -1.06 | -0.41 | 0.74 | 0.45 | 2.26 | -1.54 |
| OPM % | -142.09% | -363.89% | -133.87% | -11.45% | -4.53% | 23.34% | 19.57% | 51.95% | -55.6% |
| Other Income | 0.09 | -0.34 | 0 | 0 | 0 | -125 | 0 | -18.75 | 0 |
| Interest | -26.86 | -6.86 | 0.16 | 0.13 | 0.12 | 0 | 0 | 0 | 0 |
| Depreciation | 1.26 | 1.16 | 1.1 | 1.08 | 1.02 | 1.24 | 1.21 | 0.02 | 2.45 |
| PBT | -3.14 | -34.85 | -14.66 | -2.27 | -1.55 | -126 | -0.76 | -16.51 | -3.99 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -3.14 | -34.85 | -14.66 | -2.27 | -1.55 | -126 | -0.76 | -16.51 | -4 |
| EPS in Rs | -1.27 | -14.06 | -5.92 | -0.92 | -0.63 | -50.83 | -0.31 | -6.66 | -1.61 |
Profit & Loss
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 15m | Jun 2014 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 155 | 197 | 295 | 370 | 492 | 657 | 730 | 338 | 32 | 13 |
| Expenses | 139 | 171 | 257 | 322 | 425 | 559 | 662 | 379 | 40 | 11 |
| Operating Profit | 16 | 27 | 38 | 49 | 67 | 98 | 69 | -41 | -9 | 2 |
| OPM % | 10% | 13% | 13% | 13% | 14% | 15% | 9% | -12% | -28% | 15% |
| Other Income | 2 | 1 | 2 | 3 | 3 | 3 | -14 | -114 | -127 | -144 |
| Interest | 6 | 7 | 12 | 21 | 26 | 34 | 45 | 1 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 5 | 5 |
| PBT | 10 | 19 | 27 | 28 | 41 | 63 | 4 | -162 | -141 | -147 |
| Tax % | 7% | 26% | 32% | 22% | 20% | 22% | 21% | 0% | 0% | — |
| Net Profit | 10 | 14 | 18 | 22 | 33 | 49 | 4 | -162 | -141 | -147 |
| EPS in Rs | — | — | — | — | — | — | 1.42 | -65.52 | -56.91 | -59.41 |
| Div. Payout % | 0% | 8% | 12% | 10% | 10% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 12 |
| Reserves | 5 | 24 | 40 | 59 | 95 | 144 | 169 | 6 | -133 |
| Borrowings | 58 | 67 | 120 | 160 | 195 | 258 | 302 | 307 | 307 |
| Other Liabilities | 43 | 29 | 48 | 55 | 59 | 66 | 68 | 117 | 129 |
| Total Liabilities | 114 | 131 | 219 | 285 | 360 | 478 | 551 | 442 | 315 |
| Fixed Assets | 35 | 30 | 34 | 58 | 67 | 81 | 95 | 88 | 83 |
| CWIP | 0 | 0 | 7 | 5 | 10 | 7 | 7 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 11 | 11 | 11 | 11 |
| Other Assets | 79 | 101 | 177 | 221 | 283 | 379 | 438 | 344 | 220 |
| Total Assets | 114 | 131 | 219 | 285 | 360 | 478 | 551 | 442 | 315 |
Cash Flow
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | -7 | -2 | -16 | 5 | 14 | -5 | 2 | -6 | 2 |
| Investing | -1 | -1 | -25 | -25 | -30 | -25 | -19 | 0 | 0 |
| Financing | 9 | 3 | 42 | 21 | 17 | 27 | 16 | 4 | -1 |
| Net Cash Flow | 0 | 0 | 0 | 2 | 2 | -3 | -1 | -2 | 1 |
| Free Cash Flow | -8 | -3 | -29 | -20 | -3 | -20 | -17 | -6 | 1 |
| CFO/OP | -39 | 10 | -20 | 23 | 32 | 2 | 3 | 12 | -21 |
Ratios
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 125 | 140 | 141 | 133 | 143 | 163 | 278 | 2,342 |
| Inventory Days | 57 | 58 | 59 | 68 | 67 | 61 | 50 | 68 | 75 |
| Days Payable | 50 | 44 | 41 | 35 | 33 | 29 | 22 | 32 | 434 |
| Cash Conversion Cycle | 127 | 139 | 159 | 174 | 166 | 175 | 191 | 314 | 1,983 |
| Working Capital Days | 110 | 131 | 159 | 164 | 165 | 161 | 174 | 224 | 1,003 |
| ROCE % | — | 30% | 28% | 25% | 25% | 27% | 14% | -12% | -5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Twilight Litaka Pharma insights
29 extracted metrics + investor summaries across FY06–FY12.
Documents
Frequently Asked Questions about Twilight Litaka Pharma
What does Twilight Litaka Pharma Ltd do?
Which sector does Twilight Litaka Pharma Ltd belong to?
Company Information
Twilight Litaka Pharma Limited, incorporated in India, Listed on the Bombay Stock exchange Limited, and National Stock Exchange Limited, the company is engaged in Pharmaceuticals business
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/TWILITAKA.md for Twilight Litaka Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.